Valeant Pharmaceuticals Intl Inc Stock Analysis (NYSE:VRX)

Add to My Stocks
$13.31 $0.14 (1.04%) VRX stock closing price May 23, 2017 (Closing)
Watch Robo Advisor Video of VRX Stock Analysis
Valeant Pharmaceuticals Intl Inc
Updated on : May 23, 2017
previous close
VRX 13.3 (0%)
S&P 500 2398.4 (0%)
Closing Price On: May 23, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Drugs
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$billion
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-4.5%
Sector Average:
1.1%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Debt/Equity Ratio
Debt:
28.54B
Debt/Equity Ratio:
 7.15
Compared to the industry
Cash Flow
Operating cash flow:
$954M
Net Income:
$628M
PROS      CONS
Cash Flow
FCF Margin
PE Valuation
PS Valuation
Recent Growth
Operating Margins
Net Margins
High Debt Burden
ROIC
ROE
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
VRX PS :
0.5
Industry PS :
4.5
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
-0.7%
Return on Equity:
-31%
Free Cash Flow Margin:
43.4%
Double Tap To Exit Full Screen
0:00
/

Valeant Pharmaceuticals Intl Inc Analysis Video

1322 6 2 2

View Valeant Pharmaceuticals Intl Inc stock analysis video. This is our VRX analyst opinion covering the buy and sell arguments for VRX stock.

Valeant Pharmaceuticals Intl Inc Stock Rating (3/5)

Our Valeant Pharmaceuticals Intl Inc stock opinion is based on fundamentals of the company. This Valeant Pharmaceuticals Intl Inc stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy VRX stock?

  • The company has an operating cash flow which is 1.5 times the net income.
  • The price to earnings multiple of 1.9 is attractive when compared with the industry average PE ratio of 22.4.
  • When compared with the Medical-Drugs industry average PS ratio of 4.5, the price-to-sales ratio of 0.5 for VRX stock is attractive.
  • The company has a healthy free cash flow margin of 43.4%.

Should you sell VRX stock?

  • Valeant Pharmaceuticals Intl Inc sales shrank by -11.1% year-over-year in 2017 Q1.
  • Over the last twelve months, Valeant Pharmaceuticals Intl Inc posted an average operating loss margin of -4.5%.
  • Valeant Pharmaceuticals Intl Inc posted an average Net loss of -15% in the last twelve months.
  • Valeant Pharmaceuticals Intl Inc is debt laden and has a high debt/equity ratio of  7.15.
  • Valeant Pharmaceuticals Intl Inc has a negative ROIC (Return on Invested Capital) of -0.7%.
  • Valeant Pharmaceuticals Intl Inc has a negative return on equity of -31%. This indicates that the firm is inefficient at generating profits.

Comments on this video and Valeant Pharmaceuticals Intl Inc stock

arnulacroix22 on Valeant Pharmaceuticals Intl Inc stock analysis ($9.71)
neutral
$VRX Surprises Wall Street, Boosts Adjusted EBITDA View http://crweworld.com/article/markets/723...
reply
arnulacroix22 on Valeant Pharmaceuticals Intl Inc stock analysis ($173.26)
bullish
Watch Valeant Pharmaceuticals (VRX) stock @ current levels. The company said that it will acquire Salix Pharmaceuticals for $158.00 per share in cash. Check this out http://drstockpick.com/27356/stock-alert...
reply